jrnl94

Publication Venue For

  • Addressing challenges in developing a core domain set in adherence interventions in rheumatology: A report from the OMERACT-Adherence Group.  46:1202-1206. 2019
  • Identifying provisional generic contextual factor domains for clinical trials in rheumatology: Results from an OMERACT initiative.  46:1159-1163. 2019
  • Rates of total joint replacement in the United States: Future projections to 2020-2040 using the national inpatient sample.  46:1134-1140. 2019
  • Factors Influencing the Effectiveness of Allopurinol in Achieving and Sustaining Target Serum Urate in the National Veterans Administration Gout Cohort. 2019
  • Core domain Set selection according to OMERACT filter 2.1: The OMERACT methodology.  46:1014-1020. 2019
  • Establishing an updated core domain set for studies in juvenile idiopathic arthritis: A report from the OMERACT 2018 JIA workshop.  46:1006-1013. 2019
  • Improving Benefit-harm Assessment of Therapies from the Patient Perspective: OMERACT premeeting toward consensus on core sets for randomized controlled trials.  46:1053-1058. 2019
  • Instrument selection using the OMERACT filter 2.1: The OMERACT methodology.  46:1028-1035. 2019
  • OMERACT filter 2.1: Elaboration of the conceptual framework for outcome measurement in health intervention studies.  46:1021-1027. 2019
  • The Third Biennial 2018 OMERACT First-time Participant Program: A qualitative and quantitative study.  46:1036-1040. 2019
  • Uptake and Clinical Utility of Multibiomarker Disease Activity Testing in the United States..  46:237-244. 2019
  • HLA-DRB1 amino acid positions and residues associated with antibody-positive rheumatoid arthritis in black south africans.  46:138-144. 2019
  • Juvenile idiopathic arthritis: An idea whose time has gone?.  46:124-126. 2019
  • OMERACT Development of a Core Domain Set of Outcomes for Shared Decision-making Interventions.  46:1409-1414. 2019
  • Osteopontin and disease activity in patients with recent-onset systemic Lupus Erythematosus: Results from the SLICC Inception Cohort.  46:492-500. 2019
  • Predictors of achieving remission among patients with psoriatic arthritis initiating a tumor necrosis factor inhibitor.  46:475-482. 2019
  • Standardizing terminology and assessment for orofacial conditions in juvenile idiopathic arthritis: International, multidisciplinary consensus-based recommendations.  46:518-522. 2019
  • Risk factors for intraarticular heterotopic bone formation in the temporomandibular joint in Juvenile idiopathic arthritis.  45:1301-1307. 2018
  • Adiposity in juvenile psoriatic arthritis.  45:411-418. 2018
  • Smoking is the most significant modifiable lung cancer risk factor in systemic lupus erythematosus.  45:393-396. 2018
  • Variability in the reporting of serum urate and flares in gout clinical trials: Need for minimum reporting requirements.  45:419-424. 2018
  • Trends in joint replacement surgery in patients with rheumatoid arthritis.  45:158-164. 2018
  • Comparative effectiveness of tumor necrosis factor agents and disease-modifying antirheumatic therapy in children with enthesitis-related arthritis: The first year after diagnosis.  45:107-114. 2018
  • Routine use of quantitative disease activity measurements among us rheumatologists: Implications for treat-to-target management strategies in rheumatoid arthritis.  45:40-44. 2018
  • Critical outcomes in longitudinal observational studies and registries in patients with rheumatoid arthritis: An OMERACT special interest group report.  44:1894-1898. 2017
  • Evidence for updating the core domain set of outcome measures for juvenile idiopathic arthritis: Report from a special interest group at OMERACT 2016.  44:1884-1888. 2017
  • Validating rheumatoid arthritis remission using the patients' perspective: Results from a special interest group at OMERACT 2016.  44:1889-1893. 2017
  • Achieving consensus on total joint replacement trial outcome reporting using the OMERACT filter: Endorsement of the final core domain set for total hip and total knee replacement trials for endstage arthritis.  44:1723-1726. 2017
  • Health equity considerations for developing and reporting patient-reported outcomes in clinical trials: A report from the omeract equity special interest group.  44:1727-1733. 2017
  • Isolated arthritis of the temporomandibular joint as the initial manifestation of juvenile idiopathic arthritis.  44:1632-1635. 2017
  • Engaging stakeholders and promoting uptake of OMERACT core outcome instrument sets.  44:1551-1559. 2017
  • Malignancy in pediatric-onset systemic lupus erythematosus.  44:1484-1486. 2017
  • The OMERACT first-time participant program: Fresh eye from the new guys.  44:1560-1563. 2017
  • Outcome measures used in arthroplasty trials: Systematic review of the 2008 and 2013 literature.  44:1277-1287. 2017
  • Longterm effectiveness of herpes zoster vaccine among patients with autoimmune and inflammatory diseases.  44:1083-1087. 2017
  • Weathering a macrophage storm.  44:970-972. 2017
  • Safety of biologic and nonbiologic disease-modifying antirheumatic drug therapy in veterans with rheumatoid arthritis and hepatitis c virus infection.  44:565-570. 2017
  • The effect of widespread pain on knee pain worsening, incident knee osteoarthritis (OA), and incident knee pain: The multicenter OA (MOST) study.  44:493-498. 2017
  • Attitudes and approaches for withdrawing drugs for children with clinically inactive nonsystemic JIA: A survey of the childhood arthritis and rheumatology research alliance.  44:352-360. 2017
  • Clinical orofacial examination in juvenile idiopathic arthritis: International consensus-based recommendations for monitoring patients in clinical practice and research studies.  44:326-333. 2017
  • The juvenile psoriatic arthritis cohort in the CARRA registry: Clinical characteristics, classification, and outcomes.  44:342-351. 2017
  • Adherence and persistence with methotrexate in rheumatoid arthritis: A systematic review.  43:1997-2009. 2016
  • Treatments for lupus nephritis: A systematic review and network metaanalysis.  43:1801-1815. 2016
  • The systemic juvenile idiopathic arthritis cohort of the childhood arthritis and rheumatology research alliance registry: 2010-2013.  43:1755-1762. 2016
  • Time trends, predictors, and outcome of emergency department use for gout: A nationwide US study.  43:1581-1588. 2016
  • Agreement between rheumatologist and patient-reported adherence to methotrexate in a US rheumatoid arthritis registry.  43:1027-1029. 2016
  • Prospecting for precision: Promises for personalized medicine.  43:999-1000. 2016
  • Ms. A.M. Taylor, et al reply.  43:826. 2016
  • The performance and association between patient-reported and performance-based measures of physical functioning in research on individuals with arthritis.  43:131-137. 2016
  • Imaging as an outcome measure in gout studies: Report from the OMERACT gout working group.  42:2460-2464. 2015
  • Outcome domains and measures in total joint replacement clinical trials: Can we harmonize them? An OMERACT collaborative initiative.  42:2496-2502. 2015
  • Toward ensuring health equity: Readability and cultural equivalence of OMERACT patient-reported outcome measures.  42:2448-2459. 2015
  • Consensus on the need for a hierarchical list of patient-reported pain outcomes for metaanalyses of knee osteoarthritis trials: An OMERACT objective.  42:1971-1975. 2015
  • Current state of reporting pain outcomes in cochrane reviews of chronic musculoskeletal pain conditions and considerations for an OMERACT research agenda.  42:1934-1942. 2015
  • Harmonizing pain outcome measures: Results of the pre-OMERACT meeting on partnerships for consensus on patient-important pain outcome domains between the cochrane musculoskeletal group and OMERACT.  42:1943-1946. 2015
  • Is chronic pain a disease in its own right? Discussions from a pre-OMERACT 2014 workshop on chronic pain.  42:1947-1953. 2015
  • No association between daily walking and knee structural changes in people at risk of or with mild knee osteoarthritis. prospective data from the multicenter osteoarthritis study.  42:1685-1693. 2015
  • A call for evidence-based decision making when selecting outcome measurement instruments for summary of findings tables in systematic reviews: Results from an OMERACT working group.  42:1954-1961. 2015
  • An internet-based controlled trial aimed to improve osteoporosis prevention among chronic glucocorticoid users.  42:1478-1483. 2015
  • Barriers to medication decision making in women with lupus nephritis: A formative study using nominal group technique.  42:1616-1623. 2015
  • Dissecting the heterogeneity of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.  42:994-1001. 2015
  • Do "evidence-based recommendations" need to reveal the evidence? Minimal criteria supporting an "evidence claim".  42:1737-1739. 2015
  • Does viral hemorrhagic fever represent reactive hemophagocytic syndrome?.  42:1078-1080. 2015
  • Is the double contour sign specific for gout? Or only for crystal arthritis?.  42:353-354. 2015
  • Magnetic resonance imaging findings following intraarticular infliximab therapy for refractory temporomandibular joint arthritis among children with juvenile idiopathic arthritis.  42:2155-2159. 2015
  • Modifiable factors associated with allopurinol adherence and outcomes among patients with gout in an integrated healthcare system.  42:504-512. 2015
  • Optimal strategies for reporting pain in clinical trials and systematic reviews: Recommendations from an OMERACT 12 workshop.  42:1962-1970. 2015
  • Safety and efficacy of rituximab in childhood-onset systemic lupus erythematosus and other rheumatic diseases.  42:541-546. 2015
  • The OMERACT first-time participant ("Newbie") program: Initial assessment and lessons learned.  42:1976-1981. 2015
  • Persistence and dose escalation of tumor necrosis factor inhibitors in US veterans with rheumatoid arthritis.  41:1935-1943. 2014
  • Recent trends in medication usage for the treatment of juvenile idiopathic arthritis and the influence of tumor necrosis factor inhibitors.  41:2078-2084. 2014
  • Continued benefit of tocilizumab plus disease-modifying antirheumatic drug therapy in patients with rheumatoid arthritis and inadequate clinical responses by week 8 of treatment.  41:216-226. 2014
  • Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus.  41:300-309. 2014
  • Update of strategies to translate evidence from cochrane musculoskeletal group systematic reviews for use by various audiences.  41:206-215. 2014
  • Updated method guidelines for cochrane musculoskeletal group systematic reviews and metaanalyses.  41:194-205. 2014
  • American college of rheumatology criteria at inception, and accrual over 5 years in the slicc inception cohort.  41:875-880. 2014
  • Application of the OMERACT filter to measures of core outcome domains in recent clinical studies of acute gout.  41:574-580. 2014
  • Changes in body mass index in children with juvenile idiopathic arthritis treated with tumor necrosis factor inhibitors.  41:113-118. 2014
  • Does clinically important change in function after knee replacement guarantee good absolute function? the multicenter osteoarthritis study.  41:60-64. 2014
  • How to choose core outcome measurement sets for clinical trials: OMERACT 11 approves filter 2.0.  41:1025-1030. 2014
  • Including health equity considerations in development of instruments for rheumatology research: An introduction to a novel OMERACT paradigm.  41:150-152. 2014
  • Introduction: OMERACT 11 - International consensus conference on outcome measures in rheumatology clinical trials.  41:145-149. 2014
  • OMERACT endorsement of measures of outcome for studies of acute gout.  41:569-573. 2014
  • Outcome measures in acute gout: A systematic literature review.  41:558-568. 2014
  • Reliability and clinically important improvement thresholds for osteoarthritis pain and function scales: A multicenter study.  41:509-515. 2014
  • Research priorities in gout: The patient perspective.  41:615-616. 2014
  • Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-Label, longterm extension studies.  41:837-852. 2014
  • The diagnostic performance of anterior knee pain and activity-related pain in identifying knees with structural damage in the patellofemoral joint: The Multicenter Osteoarthritis Study.  41:1695-1702. 2014
  • Updating the OMERACT Filter: Core areas as a basis for defining core outcome sets.  41:994-999. 2014
  • Updating the OMERACT filter: Implications for imaging and soluble biomarkers.  41:1016-1024. 2014
  • Updating the omeract filter: Discrimination and feasibility.  41:1005-1010. 2014
  • Updating the omeract filter: Implications of filter 2.0 to select outcome instruments through assessment of "truth": Content, face, and construct validity.  41:1000-1004. 2014
  • Comparison of the disease activity score using erythrocyte sedimentation rate and C-reactive protein in African Americans with rheumatoid arthritis.  40:1812-1822. 2013
  • Challenges in defining quality of care for glucocorticoid-induced osteoporosis: Defending good against perfect.  40:1640-1642. 2013
  • High doses of infliximab in the management of juvenile idiopathic arthritis.  40:1749-1755. 2013
  • A Delphi exercise to identify characteristic features of gout - Opinions from patients and physicians, the first stage in developing new classification criteria (Journal of Rheumatology (2013) 40, (498-505)).  40:1634. 2013
  • Associations of alcohol use with radiographic disease progression in African Americans with recent-onset rheumatoid arthritis.  40:1498-1504. 2013
  • Incidence and prevalence of juvenile idiopathic arthritis among children in a managed care population, 1996-2009.  40:1218-1225. 2013
  • Race, ethnicity, and disease outcomes in juvenile idiopathic arthritis: A cross-sectional analysis of the childhood arthritis and rheumatology research alliance (CARRA) registry.  40:936-942. 2013
  • Variable association of reactive intermediate genes with systemic lupus erythematosus in populations with different African ancestry.  40:842-849. 2013
  • Clinical response within 12 weeks as a predictor of future low disease activity in patients with early RA: Results from the TEAR trial.  40:572-578. 2013
  • Higher-dose anakinra is effective in a case of medically refractory macrophage activation syndrome.  40:743-744. 2013
  • A Delphi exercise to identify characteristic features of gout - Opinions from patients and physicians, the first stage in developing new classification criteria.  40:498-505. 2013
  • Shrinking lung syndrome as a manifestation of pleuritis: A new model based on pulmonary physiological studies.  40:273-281. 2013
  • Comparative effectiveness of nonbiologic versus biologic disease-modifying antirheumatic drugs for rheumatoid arthritis.  40:127-136. 2013
  • Enthesitis-related arthritis is associated with higher pain intensity and poorer health status in comparison with other categories of juvenile idiopathic arthritis: The Childhood Arthritis and Rheumatology Research Alliance Registry.  39:2341-2351. 2012
  • Disease-modifying antirheumatic drug use in the treatment of juvenile idiopathic arthritis: A cross-sectional analysis of the CARRA registry.  39:1867-1874. 2012
  • Risk factors for temporomandibular joint arthritis in children with juvenile idiopathic arthritis.  39:1880-1887. 2012
  • Effect of belimumab on vaccine antigen antibodies to influenza, pneumococcal, and tetanus vaccines in patients with systemic lupus erythematosus in the BLISS-76 trial.  39:1632-1640. 2012
  • Genetic risk factors for thrombosis in systemic lupus erythematosus.  39:1603-1610. 2012
  • Improved health-related quality of life and physical function in patients with refractory chronic gout following treatment with pegloticase: Evidence from phase III randomized controlled trials.  39:1450-1457. 2012
  • Timing and magnitude of initial change in disease activity score 28 predicts the likelihood of achieving low disease activity at 1 year in rheumatoid arthritis patients treated with certolizumab pegol: A post-hoc analysis of the RAPID 1 trial.  39:1326-1333. 2012
  • Attainment of inactive disease status following initiation of TNF-α inhibitor therapy for juvenile idiopathic arthritis: Enthesitis-related arthritis predicts persistent active disease.  38:2675-2681. 2011
  • Fecal calprotectin in children with the enthesitis-related arthritis subtype of juvenile idiopathic arthritis.  38:2274-2275. 2011
  • Temporomandibular joint arthritis in pediatric Sjögren disease and sarcoidosis.  38:2272-2273. 2011
  • Smoking and outcomes after knee and hip arthroplasty: A systematic review.  38:1824-1834. 2011
  • Arthritis increases the risk for fractures - Results from the women's health initiative.  38:1680-1688. 2011
  • Developing a construct to evaluate flares in rheumatoid arthritis: A conceptual report of the OMERACT RA Flare Definition Working Group.  38:1745-1750. 2011
  • Bringing it all together: A novel approach to the development of response criteria for chronic gout clinical trials.  38:1467-1470. 2011
  • Consistency of knee pain and risk of knee replacement: The multicenter osteoarthritis study.  38:1390-1395. 2011
  • Early postoperative mortality following joint arthroplasty: A systematic review.  38:1507-1513. 2011
  • Intraarticular botulinum toxin A for refractory painful total knee arthroplasty: A randomized controlled trial (The Journal of Rheumatology (2010) 37, (2377-86)).  38:1534. 2011
  • Patient-reported outcomes in chronic gout: A report from OMERACT 10.  38:1452-1457. 2011
  • Serum urate in chronic gout - Will it be the first validated soluble biomarker in rheumatology?.  38:1462-1466. 2011
  • Tophus measurement as an outcome measure for clinical trials of chronic gout: Progress and research priorities.  38:1458-1461. 2011
  • Rapid improvement in the signs and symptoms of rheumatoid arthritis following certolizumab pegol treatment predicts better longterm outcomes: Post-hoc analysis of a randomized controlled trial.  38:990-996. 2011
  • An international consensus survey of diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis.  38:764-768. 2011
  • Surgery for shoulder osteoarthritis: A cochrane systematic review.  38:598-605. 2011
  • Botulinum toxin for shoulder pain: A cochrane systematic review.  38:409-418. 2011
  • The functional polymorphism 844 A>G in Fc αRI (CD89) does not contribute to systemic sclerosis or rheumatoid arthritis susceptibility.  38:446-449. 2011
  • Disease phenotypes and gender association of FCRL3 single-nucleotide polymorphism -169T/C in Taiwanese patients with systemic lupus erythematosus and rheumatoid arthritis.  38:264-270. 2011
  • Combination therapy of abatacept and in children with refractory systemic juvenile idiopathic arthritis: A retrospective case series.  38:180-181. 2011
  • Tocilizumab for rheumatoid arthritis: A cochrane systematic review.  38:10-20. 2011
  • Intraarticular botulinum toxin A for refractory painful total knee arthroplasty: A randomized controlled trial.  37:2377-2386. 2010
  • Spondyloarthritis in a pediatric population: Risk factors for sacroiliitis.  37:2402-2408. 2010
  • Clinically important improvement in function is common in people with or at high risk of knee OA: The MOST study.  37:1244-1251. 2010
  • Golimumab for rheumatoid arthritis: A systematic review.  37:1096-1104. 2010
  • Effectiveness and toxicity of methotrexate in juvenile idiopathic arthritis: Comparison of 2 initial dosing regimens.  37:870-875. 2010
  • (Journal of Rheumatology (2009) 36, (2114) DOI:10.3899/jrheum.090591).  37:681. 2010
  • Abatacept for rheumatoid arthritis: A cochrane systematic review (Journal of Rheumatology (2010) 37, (234-245) DOI:10.3899/jrheum.091066).  37:682. 2010
  • Vitamin D status and its associations with disease activity and severity in african americans with recent-onset rheumatoid arthritis.  37:275-281. 2010
  • A novel composite endpoint to evaluate the gastrointestinal (GI) effects of nonsteroidal antiinflammatory drugs through the entire GI tract.  37:167-174. 2010
  • Abatacept for rheumatoid arthritis: A cochrane systematic review.  37:234-245. 2010
  • Assessment of the methodologic quality of medical and surgical clinical trials in patients with arthroplasty.  36:2642-2654. 2009
  • What makes patients with fibromyalgia feel better? Correlations between patient global impression of improvement and changes in clinical symptoms and function: A pooled analysis of 4 randomized placebo-controlled trials of duloxetine.  36:2517-2522. 2009
  • Assessing single joints in arthritis clinical trials.  36:2092-2096. 2009
  • Discordance between self-report of physician diagnosis and administrative database diagnosis of arthritis and its predictors.  36:2000-2008. 2009
  • Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: A 12-month randomized, placebo-controlled clinical trial.  36:1705-1714. 2009
  • Anakinra for rheumatoid arthritis: A systematic review.  36:1118-1125. 2009
  • Spondyloarthritis is associated with poor function and physical health-related quality of life.  36:1012-1020. 2009
  • Cardiac magnetic resonance imaging with pharmacological stress perfusion and delayed enhancement in asymptomatic patients with systemic sclerosis.  36:106-112. 2009
  • Fibromyalgia, systemic lupus erythematosus (SLE), and evaluation of SLE activity.  36:82-88. 2009
  • How to ascertain drug safety in the context of benefit. Controversies and concerns.  36:2114-2121. 2009
  • Evaluation of an instrument assessing influence of gout on health-related quality of life.  35:2406-2414. 2008
  • Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): LXI. Value of C-reactive protein as a marker of disease activity and damage.  35:2355-2358. 2008
  • A new approach yields high rates of radiographic progression in knee osteoarthritis.  35:2047-2054. 2008
  • Evaluation of the presentation of systemic onset juvenile rheumatoid arthritis: Data from the Pennsylvania Systemic Onset Juvenile Arthritis Registry (PASOJAR).  35:343-348. 2008
  • Neither cell-surface nor soluble CD154 levels are associated with coronary artery disease in systemic lupus erythematosus.  35:359-360. 2008
  • Does medical insurance matter in the progression to endstage renal disease among patients with lupus nephritis?.  34:1953-1954. 2007
  • Variation in the initial treatment of knee monoarthritis in juvenile idiopathic arthritis: A survey of pediatric rheumatologists in the United States and Canada.  34:1918-1924. 2007
  • Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis.  34:1133-1138. 2007
  • Juvenile idiopathic arthritis classification criteria: Loopholes and diagnosis software [3].  34:234. 2007
  • Benefit of intraarticular corticosteroid injection under fluoroscopic guidance for subtalar arthritis in juvenile idiopathic arthritis.  33:2330-2336. 2006
  • Interleukin 1 receptor antagonist to treat cytophagic histiocytic panniculitis with secondary hemophagocytic lymphohistiocytosis.  33:2081-2084. 2006
  • Trends in prevention of glucocorticoid-induced osteoporosis.  33:1651-1657. 2006
  • Septic abscess in a child with juvenile idiopathic arthritis receiving anti-tumor necrosis factor-α therapy [1].  33:825. 2006
  • Medication errors with the use of allopurinol and colchicine: A retrospective study of a national, anonymous internet-accessible error reporting system.  33:562-566. 2006
  • Treatment of pediatric localized scleroderma with methotrexate.  33:609-614. 2006
  • Patterns of use and public perception of over-the-counter pain relievers: Focus on nonsteroidal antiinflammatory drugs.  32:2218-2224. 2005
  • Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXIX. Elevation of erythrocyte sedimentation rate is associated with disease activity and damage accrual.  32:2150-2155. 2005
  • Pain-related beliefs and affective pain responses: Implications for ethnic disparities in preferences for joint arthroplasty.  32:1149-1152. 2005
  • Effect of ethnicity on disease activity in systemic lupus erythematosus [1] (multiple letters).  32:962-963. 2005
  • Racial disparities in the receipt of osteoporosis related healthcare among community-dwelling older women with arthritis and previous fracture.  32:870-875. 2005
  • Swallowing difficulties from "DISH-phagia".  31:2526-2527. 2004
  • The Systemic Lupus Activity Measure-Revised, the Mexican Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), and a Modified SLEDAI-2K are adequate instruments to measure disease activity in systemic lupus erythematosus.  31:1934-1940. 2004
  • Effect of methotrexate therapy on bone mineral density and body composition in rat adjuvant arthritis.  31:1693-1697. 2004
  • Quantitative analysis of immunohistologic features of very early rheumatoid synovitis in disease modifying antirheumatic drug- and corticosteroid- naïve patients.  31:1281-1285. 2004
  • Recent Approaches to Understanding Osteoarthritis Pain.  31:54-60. 2004
  • Nonsteroidal Antiinflammatory Drug Toxicity Monitoring and Safety Practices.  30:2680-2688. 2003
  • A 2-Phase Screening Process for Patients with Wegener's Granulomatosis: A Pilot Study.  30:2420-2421. 2003
  • Health related quality of life in women with elderly onset rheumatoid arthritis.  30:952-957. 2003
  • OMERACT 6 brings new perspectives to rheumatology measurement research.  30:639-641. 2003
  • Balancing bones and bucks among new glucocorticoid users.  30:1-3. 2003
  • Normal radiographs in patients with persistent "hip pain" - Value of magnetic resonance imaging.  29:2463-2465. 2002
  • Significance of increased circulating proteasome in autoimmune disease.  29:2027-2030. 2002
  • Blood transfusion, alcohol use, and anthropometric risk factors for rheumatoid arthritis in older women.  29:246-254. 2002
  • Absence of linkage or association for osteoarthritis with the vitamin D receptor/type II collagen locus: The Framingham Osteoarthritis Study.  29:161-165. 2002
  • MTX affects inflammation and tissue destruction differently in the rat AA model.  28:1476-1481. 2001
  • Variations in glucocorticoid induced osteoporosis prevention in a managed care cohort.  28:1298-1305. 2001
  • Women in rheumatology [1].  28:1735-1736. 2001
  • Occurrence of scleroderma in monozygotic twins.  27:2267-2269. 2000
  • The impact of women in the practice of academic and clinical rheumatology in the Americas.  27:1827-1829. 2000
  • Nabumetone induced pseudoporphyria in childhood [3] (multiple letters).  27:1817-1818. 2000
  • Nabumetone induced pseudoporphyria in childhood..  27:1817-1818. 2000
  • Comparison of nasal and oral tolerance for the prevention of collagen induced murine arthritis.  27:1038-1044. 2000
  • Radiographic assessment of disease progression in rheumatoid arthritis patients treated with methotrexate or minocycline.  27:530-534. 2000
  • Expression of the precursor of secretoneurin, secretogranin II, in the synovium of patients with rheumatoid arthritis and osteoarthritis.  27:2347-2350. 2000
  • Current treatment by United States and Canadian pediatric rheumatologists.  26:2036-2038. 1999
  • Paucity of radiographic progression in rheumatoid arthritis treated with methotrexate as the first disease modifying antirheumatic drug [1] (multiple letters).  26:2280-2281. 1999
  • Self-administered joint counts and standard joint counts in the assessment of rheumatoid arthritis.  26:1065-1067. 1999
  • Early undifferentiated connective tissue disease (CTD). VI. An inception cohort after 10 years: Disease remissions and changes in diagnoses in well established and undifferentiated CTD.  26:816-825. 1999
  • Self-administered joint counts in rheumatoid arthritis: Comparison with standard joint counts.  26:536-539. 1999
  • Paucity of radiographic progression in rheumatoid arthritis treated with methotrexate as the first disease modifying antirheumatic drug.  26:259-261. 1999
  • Folic acid supplementation prevents deficient blood [1] (multiple letters).  25:2473. 1998
  • Familial painful restless legs syndrome correlates with pain dependent variation of blood flow to the caudate, thalamus, and anterior cingulate gyrus.  25:2270-2275. 1998
  • Enhanced expression of immunoglobulin κ light chains with unusually long CDR3 regions in patients with rheumatoid arthritis.  25:1067-1071. 1998
  • Septic arthritis caused by Neisseria sicca..  25:826-828. 1998
  • Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during longterm, low dose methotrexate therapy for rheumatoid arthritis: Implications for cardiovascular disease prevention.  25:441-446. 1998
  • Early undifferentiated connective tissue disease. V. An inception cohort 5 years later: Disease remissions and changes in diagnoses in well established and undifferentiated connective tissue diseases.  25:261-268. 1998
  • Nondepleting humanized anti-CD4 monoclonal antibody in patients with refractory rheumatoid arthritis.  25:221-228. 1998
  • A cross sectional assessment of health status instruments in patients with rheumatoid arthritis participating in a clinical trial.  24:1910-1915. 1997
  • Treatment of rheumatoid joint inflammation with intrasynovial triamcinolone..  24:1849-1850. 1997
  • Childhood sarcoidosis--does age of onset predict clinical manifestations?.  24:1654-1656. 1997
  • Radiographic results from the Minocycline in Rheumatoid Arthritis (MIRA) trial.  24:1295-1302. 1997
  • Folinic acid to prevent side effects of methotrexate in juvenile rheumatoid arthritis [3].  23:2184-2185. 1996
  • Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: Toxicity and dose finding trial in refractory rheumatoid arthritis.  23:1849-1855. 1996
  • Suppression of in vitro IgM rheumatoid factor production by diphtheria toxin interleukin 2 recombinant fusion protein (DAB 486IL-2) in patients with refractory rheumatoid arthritis.  23:1845-1848. 1996
  • Vβ17 T cell receptor peptide vaccination in rheumatoid arthritis: Results of phase I dose escalation study.  23:1353-1362. 1996
  • Systemic lupus erythematosus: Predictors of its occurrence among a cohort of patients with early undifferentiated connective tissue disease: Multivariate analyses and identification of risk factors.  23:469-475. 1996
  • Nonsteroidal antiinflammatory drugs and cognitive decline in the elderly.  22:2142-2147. 1995
  • Reiter's syndrome associated with cryptosporidial gastroenteritis.  22:1962-1963. 1995
  • Comparison of hydroxychloroquine and placebo in the treatment of the arthropathy of mild systemic lupus erythematosus.  21:1457-1462. 1994
  • Arthroscopic evaluation of knee articular cartilage: A comparison with plain radiographs and magnetic resonance imaging.  21:675-679. 1994
  • Survival impact of autoantibodies in systemic lupus erythematosus.  21:224-228. 1994
  • Functional magnetic resonance imaging should be included in the evaluation of the cervical spine in patients with rheumatoid arthritis.  20:1485-1488. 1993
  • Meta analysis of the effect of methotrexate on radiologic progression in rheumatoid arthritis [1].  20:1623. 1993
  • Anticardiolipin antibodies in systemic lupus erythematosus: Clinical correlates, HLA associations, and impact on survival.  20:1684-1693. 1993
  • Folic acid supplementation during methotrexate therapy: It makes sense.  20:929-930. 1993
  • Sternoclavicular brucellar arthritis: A report of 7 cases and a review of the literature.  20:1184-1186. 1993
  • Radiographic evidence of disease progression in methotrexate treated and nonmethotrexate disease modifying antirheumatic drug treated rheumatoid arthritis patients: A meta-analysis.  19:1868-1873. 1992
  • Digital subtraction radiography for the assessment of bone changes in rheumatoid arthritis.  19:1697-1703. 1992
  • Expressing our inner thoughts: How to organize and write a clinical research project grant application.  19:16-19. 1992
  • Mechanisms of pathogenesis in scleroderma. I. Overproduction of interleukin 6 by fibroblasts cultured from affected skin sites of patients with scleroderma.  19:1207-1211. 1992
  • Mechanisms of pathogenesis in scleroderma. II. Effects of serum and conditioned culture medium on fibroblast function in scleroderma.  19:1212-1219. 1992
  • Patients with systemic lupus erythematosus at risk for Pneumocystis carinii pneumonia.  19:1191-1194. 1992
  • Subcutaneous pancreatic fat necrosis associated with acute arthritis.  19:630-632. 1992
  • Disease and psychosocial factors related to physical functioning in rheumatoid arthritis.  18:1150-1157. 1991
  • Early undifferentiated connective tissue disease. I. Early clinical manifestation in a large cohort of patients with undifferentiated connective tissue diseases compared with cohorts of well established connective tissue disease.  18:1332-1339. 1991
  • Early undifferentiated connective tissue disease. II. The frequency of circulating antinuclear antibodies in patients with early rheumatic diseases.  18:1340-1343. 1991
  • Monthly cyclophosphamide in lupus pneumonitis and myositis.  18:153. 1991
  • Should methotrexate be discontinued before elective orthopedic surgery in patients with rheumatoid arthritis?.  18:984-988. 1991
  • Activated lymphocytes in peripheral blood of patients with RA.  17:1712. 1990
  • An eosinophilia-myalgia syndrome associated with an L-tryptophan containing product.  17:1551-1553. 1990
  • Eosinophilic myositis an expression of L-tryptophan toxicity?.  17:1554-1556. 1990
  • Mortality vs quality of life (I).  17:1110. 1990
  • The value of the Norgaard view in the evaluation of erosive arthritis.  17:614-617. 1990
  • Cognitive-behavioral therapy for primary fibromyalgia.  16:131-136. 1989
  • Discriminant and convergent validity of self-report measures of affective distress in patients with rheumatoid arthritis.  16:1428-1432. 1989
  • Thrombotic thrombocytopenic purpura in systemic sclerosis..  16:1400-1401. 1989
  • AS and a 9.2 kb Pvu II class I HLA DNA restriction fragment..  16:141-142. 1989
  • Clinical characteristics affecting survival in patients with rheumatoid arthritis undergoing cervical spine surgery: A controlled study.  16:890-896. 1989
  • Lupus pneumonitis and anti-SSA(Ro) antibodies.  16:479-481. 1989
  • Methotrexate-induced liver abnormalities in rheumatoid arthritis.  16:1180-1183. 1989
  • Rheumatoid arthritis in American blacks: A clinical and radiological study.  16:1197-1200. 1989
  • Septic arthritis due to Mycobacterium phlei presenting as infantile Reiter's syndrome.  16:1377-1378. 1989
  • Severe reversible interstitial pneumonitis induced by low dose methotrexate.  16:1007-1008. 1989
  • Articular involvement in human brucellosis..  15:379-380. 1988
  • Etiopathogenesis of rheumatoid arthritis-like disease in MRL/1 mice: II. Ultrastructural basis of joint destruction.  15:10-16. 1988
  • The value of the joint alignment and motion scale in rheumatoid arthritis.  15:1212-1215. 1988
  • Transient osteoporosis of the hip: Magnetic resonance imaging.  14:1184-1189. 1988
  • The arthritis of brucellosis: a perspective one hundred years after Bruce's discovery..  14:1083-1085. 1987
  • The assessment of pain in rheumatoid arthritis: Disease differentiation and temporal stability of a behavioral observation method.  14:700-704. 1987
  • Sexual quality-of-life of patients with arthritis compared to arthritis-free controls.  14:570-576. 1987
  • Toxicity to methotrexate in rheumatoid arthritis.  14:74-79. 1987
  • Genetic and molecular genetic studies of murine and human lupus..  14 Suppl 13:166-176. 1987
  • Toxicity due to remission inducing drugs in RA..  14:175-176. 1987
  • Development of clinical criteria for osteoarthritis.  14:3-6. 1987
  • Evaluation of the American Rheumatism Association preliminary criteria for remission in rheumatoid arthritis: A prospective study.  14:93-96. 1987
  • Meeting highlights: Workshop on epidemiology of the rheumatic diseases in the Americas.  13:810-813. 1986
  • Tuberculous podagra..  12:1022-1024. 1985
  • Paracoccidioides brasiliensis arthritis. Report of a case and review of the literature.  12:356-358. 1985
  • The carpometacarpal ratio: A useful method for assessing disease progression in rheumatoid arthritis.  12:846-848. 1985
  • Study of HLA antigens in ten multiple-case rheumatoid arthritis families.  11:129-135. 1984
  • Immune complexes and clinical manifestations in patients with rheumatoid arthritis..  11:245-246. 1984
  • Local synthesis of IgM and IgM rheumatoid factor in rheumatoid pleuritis.  10:204-209. 1983
  • DR antigen distribution in blacks with rheumatoid arthritis.  10:579-583. 1983
  • Reactive arthritis associated with brucellosis: HAL studies.  8:621-625. 1981